SCHEMBL12439723

SCHEMBL12439723

N#Cc1cc(OCc2ccccc2)ccn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 8/20 0.62
ALOX5 P09917 1/20 0.53
CYP3A4 P08684 1/20 0.51
IMPDH2 P12268 1/20 0.51
AS3MT Q9HBK9 2/20 0.49
NSD2 O96028 1/20 0.49
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
PTGS1 P23219 1/20 0.47
SLC6A2 P23975 1/20 0.47
CYP2C19 P33261 1/20 0.47
PTGS2 P35354 1/20 0.47
SLC6A3 Q01959 1/20 0.47
HIF1A Q16665 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
NR4A2 P43354 1/20 0.46
RAB9A P51151 2/20 0.46
MAOA P21397 2/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4306905 0.84 APP (0.49) MAOBRAB9AMAOASMN1; SMN2NPC1
SCHEMBL10157014 0.84 MAOB (0.56) MAOBALOX5CYP3A4IMPDH2LMNA
SCHEMBL29770616 0.78 MEN1 (0.47) MAOBCYP1A2CYP2C19RAB9AMAPT
SCHEMBL1680692 0.78 MEN1 (0.47) MAOBCYP1A2CYP2C19RAB9AMAPT
SCHEMBL2735788 0.78 MAOB (0.76) MAOBALOX5IMPDH2LMNACYP1A2
SCHEMBL7964667 0.78 ALOX5 (0.56) MAOBALOX5CYP3A4NSD2LMNA
SCHEMBL20385730 0.77 NOS3 (0.44) MAOBCYP3A4AS3MTNSD2MAOA
SCHEMBL29331696 0.77 MAOB (0.55) MAOBALOX5CYP3A4IMPDH2AS3MT
SCHEMBL30530243 0.77 MAOB (0.61) MAOBALOX5CYP3A4IMPDH2AS3MT
SCHEMBL26355934 0.77 MAOB (0.61) MAOBALOX5CYP3A4IMPDH2AS3MT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
CN-115297861-B Compounds and uses thereof 福宏治疗公司 2024-07-12 CN disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20220402873-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES AUTOTAC INC. (KR) 2022-12-22 US disclosed
EP-4096667-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
CN-115297861-A Compound and use thereof 福宏治疗公司 2022-11-04 CN disclosed
WO-2021155320-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021054804-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES 주식회사 오토텍바이오 2021-03-25 WO disclosed
EP-3497098-A1 FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen, Inc. (US) 2019-06-19 EP disclosed
US-20190169181-A1 FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. 2019-06-06 US disclosed
US-20190169181-A1 FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. 2019-06-06 US disclosed
WO-2018031877-A1 FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. (US) 2018-02-15 WO disclosed
WO-2018031877-A1 FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. (US) 2018-02-15 WO disclosed
US-20110178132-A1 PYRIDINE COMPOUND AND USE THEREOF FOR PEST CONTROL SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178132-A1 PYRIDINE COMPOUND AND USE THEREOF FOR PEST CONTROL C5, PRDX1, PRDX4 MAOB 777/4885ALOX5 687/4885CYP3A4 327/4885
US-20190169181-A1 FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, FOLH1 MAOB 275/4885ALOX5 493/4885CYP3A4 1151/4885
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB MAOB 975/4885ALOX5 3558/4885CYP3A4 3718/4885
US-20220402873-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES SQSTM1, ATG7, ATG13 MAOB 4713/4885ALOX5 4113/4885CYP3A4 3596/4885
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB MAOB 975/4885ALOX5 3558/4885CYP3A4 3718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.